Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
1,773
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Genetic mutations associated with blood count abnormalities in myeloid neoplasms

Chantana Polpraserta Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand;b Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, ThailandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6949-4449View further author information
ORCID Icon,
Sunisa Kongkiatkamona Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand;b Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, ThailandView further author information
,
Pimjai Niparuckc Department of Medicine, Faculty of Medicine, Mahidol University Ramathibodi hospital, Bangkok, ThailandView further author information
,
Thanawat Rattanathammetheed Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandView further author information
,
Kitsada Wudhikarna Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand;b Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, ThailandView further author information
,
Suporn Chuncharuneec Department of Medicine, Faculty of Medicine, Mahidol University Ramathibodi hospital, Bangkok, ThailandView further author information
,
Sirorat Kobbuakleea Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand;b Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, ThailandView further author information
,
Amornchai Suksusuta Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, ThailandView further author information
,
Theerin Lanamtienge Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, ThailandView further author information
,
Panisinee Lawasuta Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand;b Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, ThailandView further author information
,
Thiti Asawapanumasa Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand;b Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, ThailandView further author information
,
Udomsak Bunworasatea Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand;b Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, ThailandView further author information
&
Ponlapat Rojnuckarina Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand;b Research Unit in Translational Hematology, Chulalongkorn University, Bangkok, ThailandView further author information
 show all
Pages 765-771 | Published online: 29 Jun 2022

References

  • Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol. 2008;83:765–770.
  • Cordoba I, Gonzalez-Porras JR, Such E, et al. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. Leuk Res. 2012;36:287–292.
  • Ogawa S. Genetics of MDS. Blood. 2019;133:1049–1059.
  • Nagata Y, Makishima H, Kerr CM, et al. Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nat Commun. 2019;10:5386.
  • Menssen AJ, Walter MJ. Genetics of progression from MDS to secondary leukemia. Blood. 2020;136:50–60.
  • Boultwood J, Pellagatti A, McKenzie AN, et al. Advances in the 5q- syndrome. Blood. 2010;116:5803–5811.
  • Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, et al. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer. 2012;118:2879–2888.
  • Bejar R, Papaemmanuil E, Haferlach T, et al. Somatic mutations in MDS patients are associated with clinical features and predict prognosis independent of the IPSS-R: analysis of combined datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood. 2015;126:907.
  • Patnaik MM, Lasho TL. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Hematol Am Soc Hematol Educ Program. 2020;2020:450–459.
  • Nagata Y, Zhao R, Awada H, et al. Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. Blood. 2020;136:2249–2262.
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
  • Greenberg PL, Stone RM, Al-Kali A, et al. NCCN guidelines(R) insights: myelodysplastic syndromes, version 3.2022. J Natl Compr Canc Netw. 2022;20:106–117.
  • Ferrone C, Wong H, Semenuk L, et al. Validation and clinical impact of the oncomine myeloid targeted DNA and RNA Ion semiconductor sequencing assay. Blood. 2018;132:5523.
  • Atli EI, Gurkan H, Atli E, et al. The importance of targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies. Mediterr J Hematol Infect Dis. 2021;13:e2021013.
  • Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–3627. quiz 99.
  • Palomo L, Meggendorfer M, Hutter S, et al. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. Blood. 2020;136:1851–1862.
  • Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136:157–170.
  • Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011;44:53–57.
  • Ilagan JO, Ramakrishnan A, Hayes B, et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2015;25:14–26.
  • Pellagatti A, Armstrong RN, Steeples V, et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. Blood. 2018;132:1225–1240.
  • Muramatsu H, Makishima H, Maciejewski JP. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Semin Oncol. 2012;39:67–73.
  • Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016;30:2214–2220.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.